The Role of Cdc42 in the Insulin and Leptin Pathways Contributing to the Development of Age-Related Obesity
- PMID: 38068822
- PMCID: PMC10707920
- DOI: 10.3390/nu15234964
The Role of Cdc42 in the Insulin and Leptin Pathways Contributing to the Development of Age-Related Obesity
Abstract
Age-related obesity significantly increases the risk of chronic diseases such as type 2 diabetes, cardiovascular diseases, hypertension, and certain cancers. The insulin-leptin axis is crucial in understanding metabolic disturbances associated with age-related obesity. Rho GTPase Cdc42 is a member of the Rho family of GTPases that participates in many cellular processes including, but not limited to, regulation of actin cytoskeleton, vesicle trafficking, cell polarity, morphology, proliferation, motility, and migration. Cdc42 functions as an integral part of regulating insulin secretion and aging. Some novel roles for Cdc42 have also been recently identified in maintaining glucose metabolism, where Cdc42 is involved in controlling blood glucose levels in metabolically active tissues, including skeletal muscle, adipose tissue, pancreas, etc., which puts this protein in line with other critical regulators of glucose metabolism. Importantly, Cdc42 plays a vital role in cellular processes associated with the insulin and leptin signaling pathways, which are integral elements involved in obesity development if misregulated. Additionally, a change in Cdc42 activity may affect senescence, thus contributing to disorders associated with aging. This review explores the complex relationships among age-associated obesity, the insulin-leptin axis, and the Cdc42 signaling pathway. This article sheds light on the vast molecular web that supports metabolic dysregulation in aging people. In addition, it also discusses the potential therapeutic implications of the Cdc42 pathway to mitigate obesity since some new data suggest that inhibition of Cdc42 using antidiabetic drugs or antioxidants may promote weight loss in overweight or obese patients.
Keywords: Cdc42; age-related obesity; aging; insulin resistance; insulin–leptin axis; leptin resistance.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.Front Endocrinol (Lausanne). 2022 Mar 31;13:869414. doi: 10.3389/fendo.2022.869414. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35432205 Free PMC article. Review.
-
Cdc42: A Novel Regulator of Insulin Secretion and Diabetes-Associated Diseases.Int J Mol Sci. 2019 Jan 6;20(1):179. doi: 10.3390/ijms20010179. Int J Mol Sci. 2019. PMID: 30621321 Free PMC article. Review.
-
Role of a small GTPase Cdc42 in aging and age-related diseases.Biogerontology. 2023 Feb;24(1):27-46. doi: 10.1007/s10522-022-10008-9. Epub 2023 Jan 4. Biogerontology. 2023. PMID: 36598630 Review.
-
Rho GTPases-Emerging Regulators of Glucose Homeostasis and Metabolic Health.Cells. 2019 May 9;8(5):434. doi: 10.3390/cells8050434. Cells. 2019. PMID: 31075957 Free PMC article. Review.
-
Skeletal glucocorticoid signalling determines leptin resistance and obesity in aging mice.Mol Metab. 2020 Dec;42:101098. doi: 10.1016/j.molmet.2020.101098. Epub 2020 Oct 10. Mol Metab. 2020. PMID: 33045434 Free PMC article.
Cited by
-
Editorial: Exercise intervention on metabolic syndrome: focus on pyroptosis.Front Endocrinol (Lausanne). 2024 Jul 29;15:1461283. doi: 10.3389/fendo.2024.1461283. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39135620 Free PMC article. No abstract available.
References
-
- World Health Organization Obesity and Overweight. [(accessed on 23 January 2023)]. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
-
- Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C., Mullany E.C., Biryukov S., Abbafati C., Abera S.F., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–781. doi: 10.1016/S0140-6736(14)60460-8. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous